StocksU › USAP

Universal Stainless & Alloy Products, Inc. (USAP) — Earnings Call X-Ray

Our AI read all 36 of USAP's earnings calls (2016–2024) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2024 · sign up to see
Previous Call Grade
B+
Q1 2024
Expected Move
🔒
next 45 days · members
Calls Analyzed
36
2016–2024
Avg Candor
7.6/9
evasion 1.5/9
Guidance RaisedHigh CandorSkeptic ReassuredCritic AmmunitionVolume Step-UpUnderused Fixed CostsRaising PricesMargins Expanding

Call-by-call analysis

🔒 Q2 2024 earnings call 2024-07-31 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2024 call grade is ready
The full 37-point AI read of USAP's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

B+ Q1 2024 earnings call 2024-05-01 move ±14.3%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: expandingBacklog: growingPricing: raisingCapex: increasing 1 analysts · 4 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 6/9
Stress 1/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q4 2023 earnings call 2024-03-28 move ±26.2%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: expandingBacklog: stablePricing: raisingCapex: increasing 1 analysts · 4 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 5/9
Stress 1/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B+ Q4 2023 earnings call 2024-01-24 move ±11%

Management raised guidance against accelerating demand. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingBacklog: stablePricing: raisingCapex: flat
⚑ Critic ammunition✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 5/9
Stress 1/9
Complexity 3/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B+ Q3 2023 earnings call 2023-10-25 move ±23%

Management held guidance steady against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: maintainedDemand: acceleratingMargins: expandingBacklog: stablePricing: raisingHeadcount: growingCapex: flat 2 analysts · 9 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 8/9
Specificity 8/9
Evasion 1/9
Confidence 8/9
Uncertainty 2/9
Promotion 4/9
Stress 1/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B Q2 2023 earnings call 2023-07-26 move ±13.5%

Management held guidance steady against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: acceleratingMargins: expandingBacklog: stablePricing: raisingCapex: increasing 1 analysts · 5 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead✓ Early product, fast growth
Candor 7/9
Specificity 8/9
Evasion 1/9
Confidence 8/9
Uncertainty 3/9
Promotion 4/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
From the research question bank

A Q1 2023 earnings call 2023-04-26 move ±12.1%

Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.

Guidance: raisedDemand: acceleratingMargins: expandingBacklog: growingPricing: raisingHeadcount: growingCapex: increasing 3 analysts · 6 questions
✓ Clean call✓ Skeptic reassured⚑ Question left hanging✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up ahead
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 2/9
Promotion 5/9
Stress 1/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
YES Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
YES Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q4 2022 earnings call 2023-01-27 move ±11%

Management held guidance steady against accelerating demand and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: acceleratingMargins: contractingBacklog: growingPricing: raisingHeadcount: growingCapex: increasing 3 analysts · 9 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsDirection beats results
Candor 8/9
Specificity 8/9
Evasion 1/9
Confidence 7/9
Uncertainty 4/9
Promotion 5/9
Stress 2/9
Complexity 6/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
YES Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
YES Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q3 2022 2022-10-26 C maintainedacceleratingcontracting 8/9 1/9
Q2 2022 2022-07-30 A raisedacceleratingexpanding 8/9 1/9
Q1 2022 2022-04-20 B maintainedacceleratingunclear 8/9 2/9
Q4 2021 2022-01-26 B+ raisedacceleratingexpanding 8/9 2/9
Q3 2021 2021-10-20 B noneacceleratingexpanding 8/9 3/9
Q2 2021 2021-07-21 B+ maintainedacceleratingexpanding 8/9 2/9
Q1 2021 2021-04-21 A raisedacceleratingexpanding 8/9 1/9
Q4 2020 2021-01-27 B+ maintainedmixedcontracting 8/9 1/9
Q3 2020 2020-10-21 B maintainedmixedcontracting 8/9 1/9
Q2 2020 2020-08-02 D loweredslowingcontracting 8/9 2/9
Q1 2020 2020-04-22 C loweredslowingcontracting 8/9 2/9
Q4 2019 2020-01-23 C+ nonemixedexpanding 8/9 2/9
Q3 2019 2019-10-23 C+ maintainedmixedcontracting 8/9 2/9
Q2 2019 2019-07-24 B maintainedstableexpanding 7/9 2/9
Q1 2019 2019-04-24 C+ maintainedmixedcontracting 7/9 2/9
Q4 2018 2019-01-23 B maintainedmixedcontracting 8/9 1/9
Q3 2018 2018-10-24 B+ raisedacceleratingcontracting 7/9 1/9
Q2 2018 2018-07-26 A raisedacceleratingexpanding 8/9 1/9
Q1 2018 2018-04-25 A raisedacceleratingexpanding 7/9 2/9
Q4 2017 2018-01-24 A raisedacceleratingexpanding 8/9 1/9
Q3 2017 2017-10-25 B maintainedacceleratingcontracting 8/9 1/9
Q2 2017 2017-07-26 A raisedacceleratingexpanding 7/9 2/9
Q1 2017 2017-04-26 A raisedacceleratingexpanding 7/9 1/9
Q4 2016 2017-01-25 A raisedacceleratingexpanding 7/9 1/9
Q3 2016 2016-10-26 B+ loweredmixedexpanding 8/9 1/9
Q2 2016 2016-07-27 B+ maintainedmixedexpanding 8/9 1/9
Q1 2016 2016-04-27 B nonemixedexpanding 8/9 1/9
Q4 2015 2016-01-27 C noneslowingcontracting 8/9 2/9

Research question bank — earlier calls

During our 1,600-question research program, batches of experimental hypotheses were tested directly against some of USAP's earlier calls. The YES answers — the rare hits — are shown; click any question to see every company that matched it. Full list: the question bank.

C Q3 2022 earnings call 2022-10-26

1 more research questions answered NO

A Q2 2022 earnings call 2022-07-30

1 more research questions answered NO

A Q2 2017 earnings call 2017-07-26

1 more research questions answered NO

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAN · The Aaron's Company, IncAAWW · Atlas Air Worldwide HoldABAX · ABAXISABCB · Ameris BancorpABM · ABM Industries IncorporaACBI · Atlantic Capital Bancsha

USAK   All “U” companies    USAS

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.